ARQT Q3 2022 Earnings — Arcutis Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ARQTArcutis Biotherapeutics, Inc.

$3B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$725,000

Gross Profit

$456,00062.9% margin

Operating Income

-$105M-14448.0% margin

Net Income

-$108M-14856.4% margin

EPS (Diluted)

$-1.94

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$68M

Free Cash Flow

-$91M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$509M

Total Liabilities

$238M

Stockholders' Equity

$271M

Cash & Equivalents

$82M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$725,000	$0	—
Gross Profit	$456,000	-$192,000	+337.5%
Operating Income	-$105M	-$57M	-83.5%
Net Income	-$108M	-$57M	-89.0%

Revenue Segments

Product

$725,000100%